Clinical Trial Update: Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating sofobuvir/velpatasvir with or without ribavirin for 12 weeks in adults with chronic HCV and decompensated cirrhosis; results com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Hepatitis with Decompensated Cirrhosis
• Hepatitis C

Drugs mentioned

• Ribavirin (ribavirin)
• Sofosbuvir/Velpatasvir (sofosbuvir/velpatasvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2019-02-26